Rbj
2021-12-15
Nice!
Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞表示其Covid-19药物可能对奥密克戎病毒有效</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607810028,"tweetId":"607810028","gmtCreate":1639523894354,"gmtModify":1639523894622,"author":{"id":3575234837042918,"idStr":"3575234837042918","authorId":3575234837042918,"authorIdStr":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice!</p></body></html>","htmlText":"<html><head></head><body><p>Nice!</p></body></html>","text":"Nice!","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607810028","repostId":1111446051,"repostType":4,"repost":{"id":"1111446051","kind":"news","pubTimestamp":1639523229,"share":"https://www.laohu8.com/m/news/1111446051?lang=zh_CN&edition=full","pubTime":"2021-12-15 07:07","market":"us","language":"en","title":"Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞表示其Covid-19药物可能对奥密克戎病毒有效</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111446051","media":"The Wall Street Journal","summary":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-","content":"<p> Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.</p><p><blockquote>辉瑞公司表示，初步实验室测试给出了令人鼓舞的迹象，表明针对新感染者的PFE 0.62%实验性Covid-19药丸可能对奥密克戎病毒有效。</blockquote></p><p> Pfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.</p><p><blockquote>辉瑞周二还表示，对后期研究结果的最终分析证实，这种名为Paxlovid的药物在降低严重Covid-19高风险成年人的住院和死亡风险方面有89%的有效性。</blockquote></p><p> The positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.</p><p><blockquote>这一积极结果出现之际，美国食品和药物管理局正在审查是否批准在高危成年人中使用Paxlovid，这一决定可能会在今年年底前做出。</blockquote></p><p> “This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)在接受采访时表示：“这是一次真正的本垒打，为另一种高效干预措施带来了巨大希望。”</blockquote></p><p> Meanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.</p><p><blockquote>与此同时，一项单独的初步分析表明，该药物可能有助于严重Covid-19风险较低的人，例如最终患病的接种疫苗的人。</blockquote></p><p> Paxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.</p><p><blockquote>早期研究分析中的Paxlovid将严重新冠肺炎低风险成年人的住院和死亡风险降低了70%，尽管它未能在四天内减轻或解决他们的症状。</blockquote></p><p> Study subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.</p><p><blockquote>具有发生严重疾病高风险的研究受试者必须具有至少一种特征性或潜在健康状况，例如肥胖或老年。另一项研究包括未接种疫苗且患严重疾病风险低的人，如年轻健康的人，或至少有一种患严重疾病风险因素的接种疫苗的人。</blockquote></p><p> Both studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.</p><p><blockquote>辉瑞表示，两项在人体中测试Paxlovid的研究都表明，接受该药物的受试者的病毒量或病毒载量明显低于安慰剂组。</blockquote></p><p> A lower viral load could mean less transmission of the virus.</p><p><blockquote>较低的病毒载量可能意味着较少的病毒传播。</blockquote></p><p> Citing the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase & Co. analysts estimated $18 billion in sales next year.</p><p><blockquote>一些分析师援引研究结果表示，Paxlovid很可能成为寻求避免严重疾病的新感染成年人的首选Covid-19药物。摩根大通分析师预计明年的销售额将达到180亿美元。</blockquote></p><p> Pfizer shares rose 0.62% in Tuesday trading.</p><p><blockquote>辉瑞股价在周二交易中上涨0.62%。</blockquote></p><p> Doctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.</p><p><blockquote>医生和健康专家一直在寻找一种像Paxlovid这样的抗病毒药物，人们可以在症状出现后几天内轻松在家服用，以防止病情变得严重并需要住院治疗。</blockquote></p><p> The emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.</p><p><blockquote>然而，奥密克戎病毒的出现给此类抗病毒药物的应用蒙上了阴影，因为不确定这种新毒株是否会逃避治疗和疫苗。</blockquote></p><p> To make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.</p><p><blockquote>为了做出评估，制药商一直在研究授权和实验性的Covid-19药物和疫苗是否对奥密克戎有效。</blockquote></p><p> Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ</p><p><blockquote>医生越来越多地转向单克隆抗体药物来治疗感染Covid-19的高危患者。《华尔街日报》着眼于这些疗法是如何工作的，以及为什么它们对拯救生命很重要。插图：雅各布·雷诺兹/《华尔街日报》</blockquote></p><p> Researchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.</p><p><blockquote>研究人员怀疑辉瑞的药丸会很有效，因为它通过阻断一种称为蛋白酶的关键酶的活性来阻止病毒，这种酶是病毒复制所需的，并且据信不会在奥密克戎病毒中发生突变。</blockquote></p><p> That is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.</p><p><blockquote>这不同于Covid-19疫苗和一些针对病毒不同部分（刺突蛋白）的治疗方法，刺突蛋白是许多奥密克戎突变的位点。</blockquote></p><p> The early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞实验室的早期测试表明，Paxlovid阻断了奥密克戎病以及其他令人担忧的变异体中的蛋白酶。</blockquote></p><p> “Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”</p><p><blockquote>“如果蛋白酶不发挥作用，病毒就无法复制并导致疾病，”多尔斯滕博士说。“我非常相信Paxlovid对奥密克戎病的影响将是非常大的。”</blockquote></p><p> Pfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.</p><p><blockquote>辉瑞表示，计划进行更多测试来衡量Paxlovid对该变种的有效性。</blockquote></p><p> In November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.</p><p><blockquote>11月，辉瑞表示，对一项关键研究的早期观察发现，Paxlovid在降低高危成人住院和死亡风险方面的有效性为89%。</blockquote></p><p> The FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.</p><p><blockquote>辉瑞首席执行官Albert Bourla上周在《华尔街日报》首席执行官委员会上表示，FDA一直在等待最终结果，然后再做出授权决定。</blockquote></p><p> In the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.</p><p><blockquote>辉瑞表示，最终分析中，在出现症状三天内接受该药物治疗的697名高危受试者中有5人住院或死于Covid-19，而接受安慰剂治疗的682名受试者中有44人住院或死于Covid-19。</blockquote></p><p> Nine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.</p><p><blockquote>该公司表示，接受安慰剂的研究志愿者中有9人死亡，而治疗组中没有一人死亡。</blockquote></p><p> Researchers also reported the drug was 88% effective if taken within five days of symptoms.</p><p><blockquote>研究人员还报告说，如果在症状出现后五天内服用，该药物的有效率为88%。</blockquote></p><p> The final study analysis of another oral antiviral, from Merck & Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.</p><p><blockquote>默克公司和合作伙伴Ridgeback Biotherapeutics LP对另一种口服抗病毒药物的最终研究分析显示，风险降低了30%，低于早期研究中发现的50%。</blockquote></p><p> Separately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.</p><p><blockquote>另外，辉瑞一直在测试Paxlovid在患严重疾病风险低的人群中的有效性，包括一些接种过疫苗的人。</blockquote></p><p></p><p> The company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.</p><p><blockquote>该公司对结果的初步研究发现，Paxlovid未能在四天内解决或持续减轻自我报告的症状，这是该研究的主要目标，也是确定抗病毒药物是否有效的一种方法。</blockquote></p><p> Two of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.</p><p><blockquote>然而，辉瑞表示，接受Paxlovid的333名低风险受试者中有2名住院，而接受安慰剂的329名受试者中有8名住院，有效率为70%。</blockquote></p><p> No subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.</p><p><blockquote>在分析中，没有受试者死于Covid-19，该分析考察了该研究目标受试者总数中约45%的受试者的表现。</blockquote></p><p> Dr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.</p><p><blockquote>多尔斯滕博士表示，辉瑞计划与美国和其他国家的卫生当局讨论向低风险人群提供该药物的可能性，以及辉瑞是否应该进行更多测试。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞表示其Covid-19药物可能对奥密克戎病毒有效</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞表示其Covid-19药物可能对奥密克戎病毒有效</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-12-15 07:07</span>\n</p>\n</h4>\n</header>\n<article>\n<p> Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.</p><p><blockquote>辉瑞公司表示，初步实验室测试给出了令人鼓舞的迹象，表明针对新感染者的PFE 0.62%实验性Covid-19药丸可能对奥密克戎病毒有效。</blockquote></p><p> Pfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.</p><p><blockquote>辉瑞周二还表示，对后期研究结果的最终分析证实，这种名为Paxlovid的药物在降低严重Covid-19高风险成年人的住院和死亡风险方面有89%的有效性。</blockquote></p><p> The positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.</p><p><blockquote>这一积极结果出现之际，美国食品和药物管理局正在审查是否批准在高危成年人中使用Paxlovid，这一决定可能会在今年年底前做出。</blockquote></p><p> “This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p><p><blockquote>辉瑞首席科学官米凯尔·多尔斯滕(Mikael Dolsten)在接受采访时表示：“这是一次真正的本垒打，为另一种高效干预措施带来了巨大希望。”</blockquote></p><p> Meanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.</p><p><blockquote>与此同时，一项单独的初步分析表明，该药物可能有助于严重Covid-19风险较低的人，例如最终患病的接种疫苗的人。</blockquote></p><p> Paxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.</p><p><blockquote>早期研究分析中的Paxlovid将严重新冠肺炎低风险成年人的住院和死亡风险降低了70%，尽管它未能在四天内减轻或解决他们的症状。</blockquote></p><p> Study subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.</p><p><blockquote>具有发生严重疾病高风险的研究受试者必须具有至少一种特征性或潜在健康状况，例如肥胖或老年。另一项研究包括未接种疫苗且患严重疾病风险低的人，如年轻健康的人，或至少有一种患严重疾病风险因素的接种疫苗的人。</blockquote></p><p> Both studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.</p><p><blockquote>辉瑞表示，两项在人体中测试Paxlovid的研究都表明，接受该药物的受试者的病毒量或病毒载量明显低于安慰剂组。</blockquote></p><p> A lower viral load could mean less transmission of the virus.</p><p><blockquote>较低的病毒载量可能意味着较少的病毒传播。</blockquote></p><p> Citing the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase & Co. analysts estimated $18 billion in sales next year.</p><p><blockquote>一些分析师援引研究结果表示，Paxlovid很可能成为寻求避免严重疾病的新感染成年人的首选Covid-19药物。摩根大通分析师预计明年的销售额将达到180亿美元。</blockquote></p><p> Pfizer shares rose 0.62% in Tuesday trading.</p><p><blockquote>辉瑞股价在周二交易中上涨0.62%。</blockquote></p><p> Doctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.</p><p><blockquote>医生和健康专家一直在寻找一种像Paxlovid这样的抗病毒药物，人们可以在症状出现后几天内轻松在家服用，以防止病情变得严重并需要住院治疗。</blockquote></p><p> The emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.</p><p><blockquote>然而，奥密克戎病毒的出现给此类抗病毒药物的应用蒙上了阴影，因为不确定这种新毒株是否会逃避治疗和疫苗。</blockquote></p><p> To make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.</p><p><blockquote>为了做出评估，制药商一直在研究授权和实验性的Covid-19药物和疫苗是否对奥密克戎有效。</blockquote></p><p> Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ</p><p><blockquote>医生越来越多地转向单克隆抗体药物来治疗感染Covid-19的高危患者。《华尔街日报》着眼于这些疗法是如何工作的，以及为什么它们对拯救生命很重要。插图：雅各布·雷诺兹/《华尔街日报》</blockquote></p><p> Researchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.</p><p><blockquote>研究人员怀疑辉瑞的药丸会很有效，因为它通过阻断一种称为蛋白酶的关键酶的活性来阻止病毒，这种酶是病毒复制所需的，并且据信不会在奥密克戎病毒中发生突变。</blockquote></p><p> That is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.</p><p><blockquote>这不同于Covid-19疫苗和一些针对病毒不同部分（刺突蛋白）的治疗方法，刺突蛋白是许多奥密克戎突变的位点。</blockquote></p><p> The early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.</p><p><blockquote>Dolsten博士说，辉瑞实验室的早期测试表明，Paxlovid阻断了奥密克戎病以及其他令人担忧的变异体中的蛋白酶。</blockquote></p><p> “Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”</p><p><blockquote>“如果蛋白酶不发挥作用，病毒就无法复制并导致疾病，”多尔斯滕博士说。“我非常相信Paxlovid对奥密克戎病的影响将是非常大的。”</blockquote></p><p> Pfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.</p><p><blockquote>辉瑞表示，计划进行更多测试来衡量Paxlovid对该变种的有效性。</blockquote></p><p> In November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.</p><p><blockquote>11月，辉瑞表示，对一项关键研究的早期观察发现，Paxlovid在降低高危成人住院和死亡风险方面的有效性为89%。</blockquote></p><p> The FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.</p><p><blockquote>辉瑞首席执行官Albert Bourla上周在《华尔街日报》首席执行官委员会上表示，FDA一直在等待最终结果，然后再做出授权决定。</blockquote></p><p> In the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.</p><p><blockquote>辉瑞表示，最终分析中，在出现症状三天内接受该药物治疗的697名高危受试者中有5人住院或死于Covid-19，而接受安慰剂治疗的682名受试者中有44人住院或死于Covid-19。</blockquote></p><p> Nine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.</p><p><blockquote>该公司表示，接受安慰剂的研究志愿者中有9人死亡，而治疗组中没有一人死亡。</blockquote></p><p> Researchers also reported the drug was 88% effective if taken within five days of symptoms.</p><p><blockquote>研究人员还报告说，如果在症状出现后五天内服用，该药物的有效率为88%。</blockquote></p><p> The final study analysis of another oral antiviral, from Merck & Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.</p><p><blockquote>默克公司和合作伙伴Ridgeback Biotherapeutics LP对另一种口服抗病毒药物的最终研究分析显示，风险降低了30%，低于早期研究中发现的50%。</blockquote></p><p> Separately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.</p><p><blockquote>另外，辉瑞一直在测试Paxlovid在患严重疾病风险低的人群中的有效性，包括一些接种过疫苗的人。</blockquote></p><p></p><p> The company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.</p><p><blockquote>该公司对结果的初步研究发现，Paxlovid未能在四天内解决或持续减轻自我报告的症状，这是该研究的主要目标，也是确定抗病毒药物是否有效的一种方法。</blockquote></p><p> Two of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.</p><p><blockquote>然而，辉瑞表示，接受Paxlovid的333名低风险受试者中有2名住院，而接受安慰剂的329名受试者中有8名住院，有效率为70%。</blockquote></p><p> No subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.</p><p><blockquote>在分析中，没有受试者死于Covid-19，该分析考察了该研究目标受试者总数中约45%的受试者的表现。</blockquote></p><p> Dr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.</p><p><blockquote>多尔斯滕博士表示，辉瑞计划与美国和其他国家的卫生当局讨论向低风险人群提供该药物的可能性，以及辉瑞是否应该进行更多测试。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111446051","content_text":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.\n\nPfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.\n\nThe positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.\n\n“This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.\n\nMeanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.\n\nPaxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.\n\nStudy subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.\n\nBoth studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.\n\nA lower viral load could mean less transmission of the virus.\n\nCiting the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase & Co. analysts estimated $18 billion in sales next year.\n\nPfizer shares rose 0.62% in Tuesday trading.\n\nDoctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.\n\nThe emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.\n\nTo make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.\n\nDoctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ\nResearchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.\n\n\nThat is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.\n\nThe early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.\n\n“Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”\n\nPfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.\n\nIn November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.\n\nThe FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.\n\nIn the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.\n\nNine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.\n\nResearchers also reported the drug was 88% effective if taken within five days of symptoms.\n\nThe final study analysis of another oral antiviral, from Merck & Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.\n\nSeparately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.\n\nThe company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.\n\nTwo of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.\n\n\nNo subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.\n\nDr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":828,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607810028"}
精彩评论